NASDAQ · MBRX
Moleculin Biotech, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MBRX: Nov 12, 2026
Moleculin Biotech, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-9.9. The reported EPS for the same quarter last year was $-65.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-9.90 | $-9.00 | $-10.80 | 2 |
| Dec 2026 | $-8.80 | $-8.20 | $-9.40 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 30, 2:31 PM EDTMoleculin Completes Dosing In Part A Of Pivotal MIRACLE Trial; Data Readout Expected In Q1 2027(RTTNews) – Moleculin Biotech, Inc. (MBRX) announced that it has completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML).
- Fintel · Oct 23, 2:34 PM EDTMoleculin Biotech Consensus Price Target Increased by 1,900% to $244.80The average one-year price target for Moleculin Biotech (NASDAQCM:MBRX) (LSE:0K2H) has been revised to $244.80 / share. This is an increase of 1,900.00% from the prior estimate of $12.24 dated September 29, 2026. These figures represent aggregate analyst targets compiled by Finte
- RTTNews · Oct 20, 2:49 PM EDTBiotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40%(RTTNews) – Correction: The earlier fact provided in "This Day in History" was incorrect. It has been updated with the correct information.
- RTTNews · Oct 16, 10:42 AM EDTMoleculin Biotech To Effect 1-for-20 Reverse Stock Split(RTTNews) – On Friday, Moleculin Biotech, Inc. (MBRX) announced that it plans to effect a 1-for-20 reverse stock split of its common stock, effective October 20.
- RTTNews · Sep 29, 11:23 AM EDTMoleculin Completes Part A Enrollment In Phase 2/3 MIRACLE Trial For Relapsed AML(RTTNews) – Moleculin Biotech (MBRX) has completed enrolment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) in adults with relapsed or refractory acute myeloid leukemia.
- RTTNews · Sep 28, 7:40 AM EDTMoleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data(RTTNews) – Moleculin Biotech, Inc. (MBRX) announced the publication of a peer-reviewed analysis evaluating the cardiac safety of Annamycin (L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine.
- RTTNews · Sep 28, 7:36 AM EDTMoleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis(RTTNews) – Moleculin Biotech, Inc. (MBRX) announced the publication of a peer-reviewed analysis evaluating the cardiac safety of Annamycin (L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine.
- RTTNews · Aug 29, 6:34 AM EDTWhy Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories(RTTNews) – The Virtual Investor "Why Now" On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, wrapped up on August 27, 2026. The program is designed to give investors and analysts direct access to management teams, each presenting why now is the ri
- Zacks · Aug 24, 12:00 PM EDTMoleculin Biotech (MBRX) Upgraded to Buy: Here's WhyMoleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Jul 31, 10:50 AM EDTMoleculin Prices $9.3 Mln Public Offering To Advance Annamycin; Stock Down 65%(RTTNews) – Moleculin Biotech, Inc. (MBRX) on Friday announced the pricing of a public offering expected to generate gross proceeds of about $9.3 million.
- RTTNews · Jun 30, 10:54 AM EDTMoleculin Posts Encouraging Phase 2/3 MIRACLE Trial Results; Shares Down Despite Data(RTTNews) – Moleculin Biotech, Inc. (MBRX) announced positive interim efficacy results from Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in patients with relapsed or refractory acute myeloid leukemia. The analysis, based on the first 45 patients enrolled, sh
- RTTNews · Apr 24, 6:54 AM EDTMoleculin Presents Positive Preclinical Data For Annamycin In Treating Pancreatic Cancer(RTTNews) – Moleculin Biotech Inc. (MBRX), a clinical-stage pharmaceutical company, on Thursday presented preclinical data for Annamycin in treating pancreatic cancer, at the 2026 annual meeting of the American Association for Cancer Research (AACR).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Moleculin Biotech, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.